Blog
    Regulatory UpdateFor PhysiciansMay 1, 2026

    FDA peptide status, BPC-157 safety, and Semaglutide signals

    Review the regulatory status of BPC-157, TB-500, and CJC-1295, plus emerging safety signals for Semaglutide including NAION and pulmonary aspiration risks.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What is the current regulatory landscape for compounded peptides, and what emerging safety signals have been identified in recent clinical data and post-marketing surveillance?

    Evidence Snapshot

    • Regulatory Analysis: Evaluation of 10 peptides regarding FDA approval, 503A/503B compounding status, and regulatory warning letters.
    • Safety Signals: Systematic review of FAERS data for Semaglutide across multiple organ systems and regulatory reviews (FDA, EMA).
    • Clinical Trials: Analysis of Phase II and Phase III data for metabolic and immunomodulatory peptides (n = 10 records).
    • Regulatory Status: Multiple peptides transitioned to Category 2 (significant safety risk) as of September 2023 and September 2024.

    What the Research Shows

    Regulatory and FDA Status Shifts As of March 2026, the regulatory status for several commonly discussed peptides has undergone significant revision. BPC-157 is currently classified as a Category 2 bulk substance under section 503A, indicating it presents significant safety risks and is ineligible for routine compounding. The FDA cites concerns regarding immunogenicity and a lack of safety data. Similarly, TB-500 is classified under Category 2 due to immunogenicity risk and a lack of human exposure data.

    Several peptides that were previously nominated for compounding saw their nominations withdrawn or their status changed in September 2024. These include AOD-9604, CJC-1295, Ipamorelin, and Selank. For CJC-1295, the FDA specifically identified safety issues such as increased heart rate. Ipamorelin and GHK-Cu remain listed under Category 2 for 503B outsourcing facilities. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved and remains a substance of concern under interim policy following its removal from 503A pending advisory review in September 2024.

    Warning letters have been issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (Oct 2020) regarding several of these substances, including BPC-157, Thymosin Alpha-1, TB-500, and GHRP-2.

    Safety Signal Analysis: Semaglutide Post-marketing surveillance and clinical trials have identified a range of adverse event signals for Semaglutide. Gastrointestinal signals are characterized as "Strong," including nausea, vomiting, and delayed gastric emptying. The Ozempic label was updated in 2025 to include pulmonary aspiration risk during general anesthesia, a complication linked to delayed gastric emptying.

    Emerging signals include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, prompting an EMA formal review in January 2025. Other identified risks included in the label or under evaluation include acute pancreatitis, cholelithiasis (often associated with rapid weight loss), and acute kidney injury secondary to gastrointestinal-related dehydration. While suicidal ideation is listed in Section 5.9 of the label for monitoring, current data do not support a higher risk compared to background rates.

    Clinical Outcomes and Efficacy Data Phase III trials for metabolic peptides demonstrate significant weight loss outcomes. Semaglutide (STEP 1) showed 14.9% weight loss, while Tirzepatide (SURMOUNT-1) showed 22.5% weight loss. In the SURMOUNT-5 head-to-head trial, Tirzepatide was found superior to Semaglutide. Retatrutide, in Phase II trials, demonstrated 24.2% weight loss at 12mg dosages. Conversely, Thymosin Alpha-1 failed to show mortality reduction in a Phase III trial for sepsis (NCT02867267), yielding a negative result.

    Mechanism

    Based on clinical trial data and regulatory notes, the identified mechanisms and physiological responses are as follows:

    • Metabolic Response: Semaglutide and Tirzepatide drive weight loss and cardiovascular risk reduction (20% MACE reduction for Semaglutide in the SELECT trial).
    • Gastrointestinal Effects: These agents cause delayed gastric emptying, which contributes to both therapeutic effects and risks such as pulmonary aspiration and impaired absorption of oral medications.
    • Growth Hormone Modulation: Tesamorelin reduces visceral adipose tissue (18% reduction) in HIV lipodystrophy. Other agents like CJC-1295 may increase heart rate.
    • Immunogenicity: The FDA identifies immunogenicity as a primary concern for BPC-157, TB-500, GHK-Cu, and GHRP-2.

    Limitations of the Evidence

    There is a profound lack of human exposure data for peptides such as TB-500. Many peptides, including Selank and Semax, are approved in other jurisdictions (Russia) but lack FDA evaluation. For many Category 2 substances, the FDA notes that the safety profile remains uncharacterized or carries significant risks like immunogenicity. Emerging signals like NAION require further longitudinal data, as the median onset observed was 186 days. Finally, some clinical trials, such as those for Retatrutide (TRIUMPH-3) and Tesamorelin (STAY Trial), remain active or ongoing, meaning full safety and efficacy profiles are not yet complete.

    Clinical Takeaway

    Physicians should note that BPC-157, TB-500, and several growth hormone secretagogues are currently classified by the FDA as Category 2 substances due to safety or immunogenicity concerns, making them ineligible for routine compounding. While Semaglutide and Tirzepatide have demonstrated significant efficacy in weight loss and cardiovascular outcomes, they are associated with strong gastrointestinal signals and emerging risks such as NAION and pulmonary aspiration under anesthesia. Clinical monitoring for pancreatitis, gallbladder disease, and renal function is indicated based on current labeling.

    Sources

    • Regulatory Status Records: BPC-157 (0abdad3c), Thymosin Alpha-1 (68b0b103), TB-500 (c8181049), CJC-1295 (1a160b34), AOD-9604 (96fb1240), GHK-Cu (a11f0210).
    • FAERS Safety Signals: Semaglutide (502f8ab5, d2135902, 3c2b6572, be753983, 60c7beaa).
    • Clinical Trial Records: STEP 1 (NCT03548935), SELECT (NCT03574597), SURMOUNT-1 (NCT04184622), SURMOUNT-5 (NCT05024032), Retatrutide Phase II (NCT04881706), Thymosin Alpha-1 Sepsis (NCT02867267).

    Referenced Peptides

    semaglutidetirzepatidebpc 157thymosin alpha 1retatrutide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.